← Human Trials & Peer-Reviewed Studies
Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study
Plain-language guide to PMID 26931279 (2016): double-blind randomized controlled trial study of Teriparatide.
Key Facts
- PMID
- 26931279
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Dempster DW et al. (9 authors)
- DOI
- 10.1002/jbmr.2825
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Teriparatide.
The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
Here the researchers report bone mineralization density distribution (BMDD) results based on quantitative backscattered electron imaging (qBEI).
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults.
How the Study Was Run
The researchers set it up as a randomized, double-blind and open-label study.
The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.
Being open-label, the Teriparatide study did not mask who received what.
The 12-month primary study was randomized and double blind until the month 6 biopsy, then open label.
What Was Measured
The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis.
The subject headings attached to it are Biopsy, Bone Density, Calcification, Physiologic, Cancellous Bone, Cortical Bone, Diphosphonates and Imidazoles.
The authors tagged it with the keywords ANABOLICS, ANTIRESPORPTIVES, CLINICAL TRIALS, MATRIX MINERALIZATION and OSTEOPOROSIS.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Teriparatide.
The publication is from 2016 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.